Event Date: Nov 06, 2019



Related Resources l Recording

There is increasing interest in the use of cannabinoids as a therapeutic intervention in dementia, particularly for agitation.

By the end of this presentation learners will be aware that: 
 
• agitation is a common and persistent symptom in those with Alzheimer’s disease
• current pharmacotherapies have modest efficacy and/or poor safety
• there is a pharmacologic rationale for use of cannabinoids
• limited literature has evaluated the efficacy of THC and related compounds for agitation
• a pilot study of a cannabinoid for agitation has recently been completed
 

This integrated KTE webinar event is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium of Neurodegeneration in Aging (CCNA). 

                                


Related Documents:

Presenter(s):

LANCTOT_DrKrista_2015.jpg

Dr. Krista L. Lanctôt

Dr. Krista L. Lanctôt has a PhD in Clinical Pharmacology from the University of Toronto, with additional training in pharmacoepidemiology.  She is currently a Senior Neuroscientist in Geriatric Psychiatry and in the Hurvitz Brain Sciences Program at Sunnybrook Research Institute, and the Head of Neuropsychopharmacology Research.  She is a Full Professor of Psychiatry and Pharmacology/Toxicology at the University of Toronto, Toronto, Ontario, Canada.  

Dr. Lanctôt is an active researcher with over 300 publications.  Her group’s research has focused on optimizing the pharmacotherapy of cognition and neuropsychiatric symptoms associated with dementia and in predementia states.  In addition to running randomized controlled trials, her group uses biomarkers, pharmacologic challenge and neuroimaging to further understand these symptoms and target pharmacotherapy. She Co-Chaired the Neuropsychiatric Symptom Professional Interest Area (PIA) within the International Society to Advance Alzheimer's Research and Treatment (ISTAART) and is the co-lead of an international Apathy Workgroup among other international leadership roles.  She currently holds grants as a PI from the National Institutes of Health, Alzheimer’s Drug Discovery Fund, Alzheimer’s Association US, and Canadian Institutes of Health Research.  She is a full member of the School of Graduate Studies in the Faculty of Medicine, University of Toronto, previous winner of the Faculty of Medicine Graduate Education Award, and has successfully supervised 29 graduate students, many of whom have become clinician-scientists.